<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Acute exacerbation of COPD — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Acute exacerbation of COPD</h1>
        <div class="sub">AECOPD: assess for respiratory failure/pneumonia, document obs (esp. SpO2), optimise bronchodilators, give a short steroid course, and use antibiotics only when bacterial features suggest benefit.</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑10</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key design points (NICE-aligned)</strong>
                <ul>
                  <li>Many acute exacerbations are <strong>not bacterial</strong>; antibiotics should be targeted to clinical features suggesting likely bacterial infection (not automatic).</li>
                  <li>Prioritise <strong>severity assessment</strong>: hypoxia/respiratory failure, sepsis, pneumonia/PE/heart failure in the differential.</li>
                  <li>Systemic steroids reduce recovery time and treatment failure in AECOPD; NICE COPD guidance includes: <strong>offer oral prednisolone 30 mg daily for 5 days</strong> when corticosteroids are needed for an exacerbation.</li>
                  <li>NICE antimicrobial guidance (NG114) provides example antibiotic choices and emphasises: review response within <strong>2–3 days</strong>; if sputum culture taken, only change antibiotic based on susceptibilities when symptoms are not improving.</li>
                  <li>Oxygen can be harmful if given inappropriately in COPD; use a <strong>target saturation approach</strong> and escalate for suspected hypercapnic respiratory failure.</li>
                </ul>
              </div>

              <div class="callout warn">
                <strong>Localisation needed</strong>
                <ul>
                  <li>Antibiotic regimens must align to <strong>D&amp;G antimicrobial guidance</strong> (formulary/resistance vary); NICE options are a safe default but may not be the local standard.</li>
                  <li>SDEC/respiratory assessment access and community oxygen/ABG processes vary; keep local routes explicit.</li>
                </ul>
              </div>

              <h4>Comparator sources used for the draft</h4>
              <ul>
                <li>NICE NG115 (COPD in over 16s): exacerbation management principles; short-course oral prednisolone recommendation.</li>
                <li>NICE NG114 (AECOPD: antimicrobial prescribing): when to consider antibiotics, and example antibiotic options/duration.</li>
                <li>BTS Emergency Oxygen guideline (2017; with ongoing updates noted by BTS): target saturation strategy and oxygen safety in hypercapnic risk.</li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">
            <div id="draftText" class="section">
              <h3>Acute exacerbation of COPD (AECOPD) — primary care</h3>

              <h4>Definition / scope</h4>
              <ul>
                <li>Sustained worsening of COPD symptoms from the person’s usual stable state (typically increased breathlessness, cough, and/or sputum volume/purulence).</li>
                <li>Always consider alternative diagnoses and complications (pneumonia, PE, heart failure, pneumothorax, ACS, sepsis).</li>
              </ul>

              <h4>Immediate red flags (same-day assessment / ED)</h4>
              <ul>
                <li><strong>SpO2 low</strong> (especially &lt;92% on air, or falling vs usual baseline) or severe breathlessness / exhaustion / cyanosis.</li>
                <li><strong>New confusion</strong>, drowsiness, or signs of <strong>hypercapnia</strong> (CO2 retention concern).</li>
                <li><strong>Sepsis concern</strong>: hypotension, persistent tachycardia, rigors, mottling, very unwell.</li>
                <li><strong>Chest pain</strong>, syncope, haemoptysis, unilateral pleuritic pain (PE/ACS/pneumothorax differential).</li>
                <li><strong>Unable to cope at home</strong> (cannot speak in sentences, cannot manage ADLs, poor support) or unable to maintain oral intake.</li>
                <li><strong>Suspected pneumonia</strong> (focal chest signs, high fever, pleuritic pain, significant hypoxia) — follow CAP pathway.</li>
              </ul>

              <h4>Assessment (primary care)</h4>
              <ul>
                <li><strong>Observations:</strong> HR, BP, RR, Temp, <strong>SpO2 on air</strong> (document if on oxygen), mental state; consider NEWS2 if used locally.</li>
                <li><strong>History:</strong> baseline COPD severity (MRC dyspnoea), usual SpO2 (if known), change in symptoms; sputum volume/colour; fever; pleuritic pain; VTE risk; heart failure symptoms; inhaler adherence; recent antibiotics/oral steroids; previous admissions/NIV/ICU.</li>
                <li><strong>Examination:</strong> work of breathing, wheeze/air entry, focal signs, peripheral oedema, signs of DVT, hydration.</li>
                <li><strong>Community investigations:</strong> none mandated; consider CXR/ECG if pneumonia/heart failure/ACS/PE is possible or diagnostic uncertainty in a sick patient.</li>
              </ul>

              <h4>Initial management (community) — if safe to treat at home</h4>
              <ul>
                <li><strong>Bronchodilators:</strong> increase use of SABA (± SAMA) using inhaler + spacer; consider nebuliser only if already prescribed/available and appropriate.</li>
                <li><strong>Oral corticosteroid:</strong> consider if significant increase in breathlessness interfering with daily activities; NICE option: <strong>prednisolone 30 mg daily for 5 days</strong> (avoid prolonged courses).</li>
                <li><strong>Antibiotics:</strong> <strong>do not give routinely</strong>. Consider if bacterial features (especially <strong>sputum purulence</strong> plus increased volume/thickness and/or increased breathlessness) and/or higher risk of complications. Use <strong>local antimicrobial guidance</strong>. (NICE NG114 examples: amoxicillin / doxycycline / clarithromycin for 5 days.)</li>
                <li><strong>Oxygen:</strong> if hypoxic and oxygen is being given in the community, use a <strong>target saturation approach</strong> and escalate urgently if CO2 retention risk is suspected (local policy).</li>
                <li><strong>Safety-net / follow-up:</strong> review if not starting to improve within <strong>48–72 hours</strong>, or earlier if worsening. Give clear ED triggers (worsening breathlessness, drowsiness, new confusion, chest pain, unable to cope).</li>
              </ul>

              <h4>Who to refer / admit</h4>
              <ul>
                <li><strong>ED / acute medical assessment:</strong> any red flag above; suspected respiratory failure/hypercapnia; severe hypoxia; sepsis; suspected pneumonia needing assessment; inability to cope at home.</li>
                <li><strong>Consider SDEC / rapid-access respiratory / hospital-at-home</strong> (if available locally): borderline cases needing CXR, bloods/ABG, IV therapy, or short-interval observation; frequent exacerbations or significant comorbidity/frailty.</li>
              </ul>

              <h4>Who not to refer (usually)</h4>
              <ul>
                <li>Mild/moderate AECOPD with stable observations, no red flags, and safe home circumstances with clear follow-up/safety-netting.</li>
              </ul>

              <h4>Referral letter / triage metrics (if referring)</h4>
              <ul>
                <li>SpO2 on air (and whether on oxygen), RR, HR, BP, Temp, mental state; NEWS2 if used.</li>
                <li>Baseline COPD severity (MRC), usual SpO2 if known; prior NIV/ICU; number of exacerbations/admissions in last 12 months.</li>
                <li>Sputum: volume/colour change; fever; pleuritic pain; chest pain; haemoptysis.</li>
                <li>Comorbidities (HF/IHD/CKD/diabetes), frailty, immunosuppression, smoking status.</li>
                <li>Medications: inhalers (incl. ICS), home oxygen, rescue pack use; what you have started (bronchodilators/steroids/antibiotics with doses + start time).</li>
                <li>Any tests done (CXR/ECG) and findings.</li>
                <li>Home situation/support and ability to manage at home.</li>
              </ul>

              <div class="callout warn">
                <strong>Local agreement needed (D&amp;G)</strong>
                <ul>
                  <li>[ ] Confirm local oxygen targets and escalation process for suspected hypercapnic respiratory failure (including who can request ABGs and where).</li>
                  <li>[ ] Confirm D&amp;G first-line antibiotic choices/doses/durations for AECOPD (and penicillin allergy), and what counts as “higher risk of treatment failure”.</li>
                  <li>[ ] Agree local criteria/routes for SDEC vs ED vs direct respiratory team for AECOPD.</li>
                  <li>[ ] Agree whether “rescue packs” are supported locally (prednisolone ± antibiotic supply) and the required action plan + review expectations.</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References</h3>
              <ul>
                <li>NICE. <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)</em>. Updated 2019 (orig. 2018). Accessed 2026‑02‑10. https://www.nice.org.uk/guidance/ng115</li>
                <li>NICE. <em>Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)</em>. Published 5 Dec 2018; last reviewed 18 Apr 2019. Accessed 2026‑02‑10. https://www.nice.org.uk/guidance/ng114</li>
                <li>British Thoracic Society. <em>Emergency Oxygen</em> (guideline resources). Accessed 2026‑02‑10. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/emergency-oxygen/</li>
              </ul>
              <p class="small">Draft note: antibiotic choice and oxygen targets should be checked against local D&amp;G guidance/policy; this page provides the triage + documentation structure and NICE-aligned default options.</p>
            </div>
          </div>

        </div>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
